Quick Takeaways
- SpringWorks Therapeutics, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2025.
- Headline metric: Return On Equity -52%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2025-05-02) highlights Return On Equity -51.6%, Return On Assets -43.7%, and Current Ratio 4.33x.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
42.9/100
Caution Confidence medium
-52%
Metric score 0.0/100
-44%
Metric score 0.0/100
Debt-to-equity and NetIncomeLoss YoY
Return On Equity, Return On Assets, and Quick Ratio
Return On Equity
-52%
YoY: -18%
Industry median: -47% (n=218)
Return On Assets
-44%
YoY: -21%
Industry median: -44% (n=217)
Current Ratio
4.33x
YoY: -37%
Industry median: 3.67x (n=218)
Quick Ratio
5.14x
YoY: -40%
Industry median: 2.03x (n=83)
Debt-to-equity
0.17x
YoY: +3.7%
Industry median: 0.31x (n=169)
NetIncomeLoss YoY
25%
YoY:
Industry median: -12% (n=211)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -52% | -18% |
| Return On Assets | -44% | -21% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 4.33x | -37% |
| Quick Ratio | 5.14x | -40% |
| Debt-to-equity | 0.17x | +3.7% |
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | 25% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 75,322,696 | +1.7% |
| Common Stock, Shares, Outstanding | 74,986,085 | +1.2% |
| Common Stock, Value, Issued | $8,000 | +14% |
| Weighted Average Number of Shares Outstanding, Basic | 74,885,348 | +1.5% |
| Weighted Average Number of Shares Outstanding, Diluted | 74,885,348 | +1.5% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.